- BioCryst Pharmaceuticals press release ( NASDAQ: BCRX ): Q4 Non-GAAP EPS of -$0.38 misses by $0.18 .
- Revenue of $79.5M (+68.4% Y/Y) beats by $5.32M .
- ORLADEYO net revenue in the fourth quarter of 2022 was $70.7 million.
- Cash, cash equivalents, restricted cash and investments totaled $443.9 million as of December 31, 2022, compared to $517.8 million as of December 31, 2021
- 2023 Outlook:
-
The company expects full year 2023 global net ORLADEYO revenue to be no less than $320 million. As in 2022, due to the seasonal impact of managed care reauthorizations in the first quarter of the year, the company expects ORLADEYO net revenue in the first quarter of 2023 to be similar to, or slightly less than, ORLADEYO net revenue in the fourth quarter of 2022.
Operating expenses for full year 2023, not including non-cash stock compensation, are expected to be flat to 2022 at approximately $375 million. While flat year over year, we expect reductions in R&D spending in 2023 following the discontinuation of the BCX9930 and BCX9250 programs in 2022 and the delay in the 10013 clinical program, offset by increases in SG&A to support the U.S. launch and global expansion of ORLADEYO
For further details see:
BioCryst Pharmaceuticals Non-GAAP EPS of -$0.38 misses by $0.18, revenue of $79.5M beats by $5.32M